×
See What’s New Across Our Pipeline
-
•
New clinical data illustrate our science of durability: tarcocimab’s human ocular half-life of 20 days is 3x longer than faricimab -
•
New enhanced formulations for tarcocimab and KSI-501: designed to deliver strong immediacy and Kodiak’s signature 6-month durability -
•
New phase 3 GLOW2 study enrolling patients in diabetic retinopathy: repeats successful GLOW1 study design with all patients on 6-month dosing -
•
New phase 3 DAYBREAK study is enrolling patients in wet AMD and investigates two key unmet needs: longer durability with tarcocimab and better efficacy with KSI-501 -
•
New KSI-101 clinical program: APEX study is enrolling patients with macular edema, based on a bispecific anti-inflammatory mechanism of action
Review our learnings and course corrections at Kodiak’s 2024 Investor R&D Day